M
278.23
4.13 (1.51%)
| 前收盘价格 | 274.10 |
| 收盘价格 | 277.67 |
| 成交量 | 279,609 |
| 平均成交量 (3个月) | 339,798 |
| 市值 | 6,177,624,576 |
| 价格/销量 (P/S) | 20.79 |
| 股市价格/股市净资产 (P/B) | 9.46 |
| 52周波幅 | |
| 利润日期 | 5 Aug 2025 - 11 Aug 2025 |
| 营业毛利率 | -123.38% |
| 营业利益率 (TTM) | -57.79% |
| 稀释每股收益 (EPS TTM) | -17.83 |
| 总债务/股东权益 (D/E MRQ) | 16.85% |
| 流动比率 (MRQ) | 5.91 |
| 营业现金流 (OCF TTM) | -395.31 M |
| 杠杆自由现金流 (LFCF TTM) | -274.11 M |
| 资产报酬率 (ROA TTM) | -25.56% |
| 股东权益报酬率 (ROE TTM) | -50.16% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看跌 | 看跌 |
| Biotechnology (全球的) | 看跌 | 看跌 | |
| 股票 | Madrigal Pharmaceuticals, Inc. | 看涨 | 看涨 |
AIStockmoo 评分
2.9
| 分析师共识 | 5.0 |
| 内部交易活动 | 3.0 |
| 价格波动 | 2.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | 2.0 |
| 平均 | 2.90 |
|
Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Growth |
| 内部持股比例 | 7.73% |
| 机构持股比例 | 108.21% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 460.00 (B. Riley Securities, 65.33%) | 购买 |
| 中 | 450.50 (61.92%) | |
| 低 | 420.00 (Canaccord Genuity, 50.95%) | 购买 |
| 平均值 | 445.25 (60.03%) | |
| 总计 | 4 购买 | |
| 平均价格@调整类型 | 316.59 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| B. Riley Securities | 02 May 2025 | 460.00 (65.33%) | 购买 | 315.48 |
| Canaccord Genuity | 02 May 2025 | 420.00 (50.95%) | 购买 | 315.48 |
| UBS | 02 May 2025 | 458.00 (64.61%) | 购买 | 315.48 |
| JMP Securities | 24 Apr 2025 | 443.00 (59.22%) | 购买 | 319.93 |
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| BAKER BROS. ADVISORS LP | 285.73 | - | 2,860 | 817,188 |
| BATE KENNETH | 285.73 | - | 715 | 204,297 |
| DALY JAMES M | 285.73 | - | 715 | 204,297 |
| FOUSE JACQUALYN A | 285.73 | - | 203 | 58,003 |
| FRIEDMAN PAUL A | 285.73 | - | 715 | 204,297 |
| LEVY RICHARD S | 285.73 | - | 715 | 204,297 |
| 累积净数量 | 5,923 | |||
| 累积净值 ($) | 1,692,379 | |||
| 累积平均购买 ($) | 285.73 | |||
| 累积平均卖出 ($) | - | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| FRIEDMAN PAUL A | 董事 | 20 Jun 2025 | 获得 (+) | 715 | 285.73 | 204,297 |
| DALY JAMES M | 董事 | 20 Jun 2025 | 获得 (+) | 715 | 285.73 | 204,297 |
| BAKER BROS. ADVISORS LP | 董事 | 20 Jun 2025 | 获得 (+) | 2,860 | 285.73 | 817,188 |
| FOUSE JACQUALYN A | 董事 | 20 Jun 2025 | 获得 (+) | 203 | 285.73 | 58,003 |
| LEVY RICHARD S | 董事 | 20 Jun 2025 | 获得 (+) | 715 | 285.73 | 204,297 |
| BATE KENNETH | 董事 | 20 Jun 2025 | 获得 (+) | 715 | 285.73 | 204,297 |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合